Calmodulin-independent, agonistic properties of a peptide containing the calmodulin binding site of estrogen receptor α

Molecular and Cellular Endocrinology

Volumn 268, Issue 1-2, 2007, Pages 37-49

  Gallo, Dominique ^a   Jacquemotte, Françoise ^b   Cleeren, Anny ^a   Laïos, Ioanna ^a   Hadiy, Samira ^a   Rowlands, Martin G ^c   Caille, Olivier ^d   Nonclercq, Denis ^e   Laurent, Guy ^e   Jacquot, Yves ^f   Leclercq, Guy ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Meurice Institute   (Belgium)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF GENEVA   (Switzerland)

^e UNIVERSITY OF MONS   (Belgium)

^f SORBONNE UNIVERSITÉ   (France)

Author keywords

Breast cancer; Calmodulin; Estrogen receptor ; Peptide

Indexed keywords

AMINO ACID; CALMODULIN; ESTROGEN RECEPTOR ALPHA; PEPTIDE; PEPTIDE DERIVATIVE; PROLYLLEUCYLMETHIONYLISOLEUCYLLYSYLARGINYLSERYLALANYLALANYLASPARAGINYL SERYLLEUCYLALANYLLEUCYLSERYLLEUCYLTHREONINE; PROLYLLEUCYLMETHIONYLISOLEUCYLLYSYLARGINYLSERYLGLYCYLGLYCYLASPARAGINYL SERYLLEUCYLALANYLLEUCYLSERYLLEUCYLTHREONINE; PROLYLLEUCYLMETHIONYLISOLEUCYLLYSYLARGINYLSERYLLYSYLLYSYLASPARAGINYL SERYLLEUCYLALANYLLEUCYLSERYLLEUCYLTHREONINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CELL FUNCTION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DISSOCIATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG SYNTHESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; PROTEIN PROCESSING; RECEPTOR DOWN REGULATION; TRANSACTIVATION;

EID: 33947301799     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.01.012     Document Type: Article

References (58)

1. Atherton E., and Sheppard R.C. Solid Phase Peptide Synthesis: A Practical Approach (1989), IRL Press, Oxford
2. Biswas D.K., Reddy P.V., Pickard M., Makkad B., Pettit N., and Pardee A.B. Calmodulin is essential for estrogen receptor interaction with its motif and activation of responsive promoter. J. Biol. Chem. 273 (1998) 33817-33824
3. Borras M., Lacroix M., Legros N., and Leclercq G. Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers. Cancer Lett. 120 (1997) 23-30
4. Bouhoute A., and Leclercq G. Modulation of estradiol and DNA binding to estrogen receptor upon association with calmodulin. Biochem. Biophys. Res. Commun. 208 (1995) 748-755
5. Brohee R., Nonclercq D., Journe D.N., Toubeau G., Falmagne P., Leclercq G., Heuson-Stiennon J.A., and Laurent G. Demonstration of estrogen receptors and of estrogen responsiveness in the HKT-1097 cell line derived from diethylstilbestrol-induced kidney tumors. In Vitro Cell. Dev. Biol. Anim. 36 (2000) 640-649
6. Castoria G., Migliaccio A., Nola E., and Auricchio F. In vitro interaction of estradiol receptor with Ca2+-calmodulin. Mol. Endocrinol. 2 (1988) 167-174
7. Cheskis B.J. Regulation of cell signalling cascades by steroid hormones. J. Cell. Biochem. 93 (2004) 20-27
8. Conway K., Parrish E., Edmiston S.N., Tolbert D., Tse C.K., Geradts J., Livasy C.A., Singh H., Newman B., and Millikan R.C. The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res. 7 (2005) R871-R880
9. de Longueville F., Lacroix M., Barbuto A.M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., and Remacle J. Molecular characterization of breast cancer cell lines by a low-density microarray. Int. J. Oncol. 27 (2005) 881-892
10. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science 240 (1988) 889-895
11. Evinger III A.J., and Levin E.R. Requirements for estrogen receptor alpha membrane localization and function. Steroids 70 (2005) 361-363
12. Fuqua S.A., Wiltschke C., Zhang Q.X., Borg A., Castles C.G., Friedrichs W.E., Hopp T., Hilsenbeck S., Mohsin S., O'Connell P., and Allred D.C. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 60 (2000) 4026-4029
13. Garcia Pedrero J.M., Del Rio B., Martinez-Campa C., Muramatsu M., Lazo P.S., and Ramos S. Calmodulin is a selective modulator of estrogen receptors. Mol. Endocrinol. 16 (2002) 947-960
14. Green S., Walter P., Kumar V., Krust A., Bornert J.M., Argos P., and Chambon P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320 (1986) 134-139
15. Herynk M.H., and Fuqua S.A. Estrogen receptor mutations in human disease. Endocr. Rev. 25 (2004) 869-898
16. Iannone M.A., Simmons C.A., Kadwell S.H., Svoboda D.L., Vanderwall D.E., Deng S.J., Consler T.G., Shearin J., Gray J.G., and Pearce K.H. Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Mol. Endocrinol. 18 (2004) 1064-1081
17. Imai Y., Matsushima Y., Sugimura T., and Terada M. A simple and rapid method for generating a deletion by PCR. Nucleic Acids Res. 19 (1991) 2785
18. Jacquot Y., Gallo D., and Leclercq G. Estrogen receptor alpha-Identification by a modeling approach of a potential polyproline II recognizing domain within the AF2 region of the receptor that would play a role of prime importance in its mechanism of action. J. Steroid Biochem. Mol. Biol. 104 (2007) 1-10
19. Journe F., Chaboteaux C., Dumon J.C., Leclercq G., Laurent G., and Body J.J. Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells. Br. J. Cancer 91 9 (2004) 1703-1710
20. Kaiser E., Colescott R.L., Bossinger C.D., and Cook P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 34 (1970) 595-598
21. Kampa M., and Castanas E. Membrane steroid receptor signaling in normal and neoplastic cells. Mol. Cell. Endocrinol. 246 (2006) 76-82
22. Kincaid R.L., Vaughan M., Osborne Jr. J.C., and Tkachuk V.A. Ca2+-dependent interaction of 5-dimethylaminonaphthalene-1-sulfonyl-calmodulin with cyclic nucleotide phosphodiesterase, calcineurin, and troponin I. J. Biol. Chem. 257 (1982) 10638-10643
23. Knorr R., Trzeciak A., Bannwarth W., and Gillessen D. New coupling reagents in peptide chemistry. Tetrahedron Lett. 30 (1989) 1927-1930
24. Kong E.H., Heldring N., Gustafsson J.A., Treuter E., Hubbard R.E., and Pike A.C. Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3593-3598
25. Lacroix M., and Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 83 (2004) 249-289
26. Laios I., Journe F., Nonclercq D., Vidal D.S., Toillon R.A., Laurent G., and Leclercq G. Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells. J. Steroid. Biochem. Mol. Biol. 94 (2005) 347-359
27. Leclercq G., Lacroix M., Laios I., and Laurent G. Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. Curr. Cancer Drug Targets 6 (2006) 39-64
28. Lee H., and Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol. Cell. Biol. 22 (2002) 5835-5845
29. Li L., Li Z., and Sacks D.B. Calmodulin regulates the transcriptional activity of estrogen receptors. Selective inhibition of calmodulin function in subcellular compartments. J. Biol. Chem. 278 (2003) 1195-1200
30. Li L., Li Z., and Sacks D.B. The transcriptional activity of estrogen receptor-alpha is dependent on Ca2+/calmodulin. J. Biol. Chem. 280 (2005) 13097-13104
31. Li L., Li Z., Howley P.M., and Sacks D.B. E6AP and calmodulin reciprocally regulate estrogen receptor stability. J. Biol. Chem. 281 (2006) 1978-1985
32. Li Z., Joyal J.L., and Sacks D.B. Calmodulin enhances the stability of the estrogen receptor. J. Biol. Chem. 276 (2001) 17354-17360
33. McCague R., Rowlands M.G., Grimshaw R., and Jarman M. Evidence that tamoxifen binds to calmodulin in a conformation different to that when binding to estrogen receptors, through structure-activity study on ring-fused analogues. Biochem. Pharmacol. 48 (1994) 1355-1361
34. Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., and Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 (2003) 751-763
35. Nawaz Z., and O'Malley B.W. Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription?. Mol. Endocrinol. 18 (2004) 493-499
36. Picard D., Kumar V., Chambon P., and Yamamoto K.R. Signal transduction by steroid hormones: nuclear localization is differentially regulated in estrogen and glucocorticoid receptors. Cell Regul. 1 (1990) 291-299
37. Pons M., Gagne D., Nicolas J.C., and Mehtali M. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Biotechniques 9 (1990) 450-459
38. Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., Beaudouin J., Ellenberg J., and Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell. 11 (2003) 695-707
39. Rodriguez A.L., Tamrazi A., Collins M.L., and Katzenellenbogen J.A. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding. J. Med. Chem. 47 (2004) 600-611
40. Rossini G.P. The quaternary structures of untransformed steroid hormone receptors: an open issue. J. Theor. Biol. 166 (1994) 339-353
41. Rowlands M.G., Parr I.B., McCague R., Jarman M., and Goddard P.M. Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity. Biochem. Pharmacol. 40 (1990) 283-289
42. Scatchard G. The attraction of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 51 (1949) 660-672
43. Seielstad D.A., Carlson K.E., Kushner P.J., Greene G.L., and Katzenellenbogen J.A. Analysis of the structural core of the human estrogen receptor ligand binding domain by selective proteolysis/mass spectrometric analysis. Biochemistry 34 (1995) 12605-12615
44. Sentis S., Le Romancer M., Bianchin C., Rostan M.C., and Corbo L. SUMOylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol. Endocrinol. 19 (2005) 2671-2684
45. Seo H.S., Larsimont D., Ma Y., Laios I., and Leclercq G. Regulation of estrogen receptor levels by ligand-induced release of compound(s) in MCF-7 cells. Mol. Cell. Endocrinol. 164 (2000) 19-29
46. Seo H.S., DeNardo D.G., Jacquot Y., Laios I., Vidal D.S., Zambrana C.R., Leclercq G., and Brown P.H. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res. Treat. 99 (2006) 121-134
47. Shang Y., Hu X., DiRenzo J., Lazar M.A., and Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 (2000) 843-852
48. Shao D., Berrodin T.J., Manas E., Hauze D., Powers R., Bapat A., Gonder D., Winneker R.C., and Frail D.E. Identification of novel estrogen receptor alpha antagonists. J. Steroid. Biochem. Mol. Biol. 88 (2004) 351-360
49. Singer A.L., Sherwin R.P., Dunn A.S., and Appleman M.M. Cyclic nucleotide phosphodiesterases in neoplastic and nonneoplastic human mammary tissues. Cancer Res. 36 (1976) 60-66
50. Singh R.R., and Kumar R. Steroid hormone receptor signaling in tumorigenesis. J. Cell. Biochem. 96 (2005) 490-505
51. Strobl J.S., Peterson V.A., and Woodfork K.A. A survey of human breast cancer sensitivity to growth inhibition by calmodulin antagonists in tissue culture. Biochem. Pharmacol. 47 (1994) 2157-2161
52. Wang C., Fu M., Angeletti R.H., Siconolfi-Baez L., Reutens A.T., Albanese C., Lisanti M.P., Katzenellenbogen B.S., Kato S., Hopp T., Fuqua S.A., Lopez G.N., Kushner P.J., and Pestell R.G. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. 276 (2001) 18375-18383
53. Wang R.A., Mazumdar A., Vadlamudi R.K., and Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. Embo J. 21 (2002) 5437-5447
54. Warnmark A., Treuter E., Gustafsson J.A., Hubbard R.E., Brzozowski A.M., and Pike A.C. Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. J. Biol. Chem. 277 (2002) 21862-21868
55. Wei J.W., Hickie R.A., and Klaassen D.J. Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13. Cancer Chemother. Pharmacol. 11 (1983) 86-90
56. Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., McKee D.D., Galardi C.M., Plunket K.D., Nolte R.T., Parks D.J., Moore J.T., Kliewer S.A., Willson T.M., and Stimmel J.B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415 (2002) 813-817
57. Yan F., Gao X., Lonard D.M., and Nawaz Z. Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators. Mol. Endocrinol. 17 (2003) 1315-1331
58. Ylikomi T., Bocquel M.T., Berry M., Gronemeyer H., and Chambon P. Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors. Embo J. 11 (1992) 3681-3694